<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04411654</url>
  </required_header>
  <id_info>
    <org_study_id>PRV-GD2-101</org_study_id>
    <nct_id>NCT04411654</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)</brief_title>
  <official_title>An Open-label, Phase 1/2 Study to Evaluate the Safety and Efficacy of Single-dose PR001A in Infants With Type 2 Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prevail Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Prevail Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRV-GD2-101 is an open-label, Phase 1/2, multicenter study to evaluate the safety and&#xD;
      efficacy of single-dose PR001 in infants diagnosed with Type 2 Gaucher disease (GD2). For&#xD;
      each patient, the study will be approximately 5 years in duration. During the first 12 months&#xD;
      after dosing, patients will be evaluated for the effects of PR001 on safety, tolerability,&#xD;
      immunogenicity, biomarkers, and efficacy. Patients will be followed up for an additional 4&#xD;
      years to monitor safety and changes on selected biomarkers and clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">September 2028</completion_date>
  <primary_completion_date type="Anticipated">September 2028</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Blinded assessor used in secondary outcome measures</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events leading to discontinuation</measure>
    <time_frame>Year 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of AAV9 and GCase in blood</measure>
    <time_frame>Up to Year 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of AAV9 and GCase in CSF</measure>
    <time_frame>Up to Year 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Baseline until event or study completion, up to Year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical event</measure>
    <time_frame>Baseline until event or study completion, up to Year 5</time_frame>
    <description>Clinical event defined as tracheostomy/invasive ventilation, and/or percutaneous endoscopic gastrostomy (PEG) tube placement, and/or nasogastric (NG) tube placement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>Months 6, 12 and up to Year 3</time_frame>
    <description>Measured using Bayley Scales of Infant and Toddler Development (BSID-III)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>Study Month 12 and up to Study Year 3</time_frame>
    <description>Measured using Wechsler Preschool and Primary Scale of Intelligence (WPPSI-IV) as appropriate. (Not all patients begin the study at birth. Only patients who are age 36 months at the designated study visits will be assessed using this measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in motor skills</measure>
    <time_frame>Months 6, 12 and up to Year 3</time_frame>
    <description>Change from baseline in motor function using Gross Motor Function Measure (GMFM-88).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in motor skills</measure>
    <time_frame>Months 6, 12 and up to Year 3</time_frame>
    <description>Change from baseline in motor function using the BSID-III.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impressions (Severity)</measure>
    <time_frame>Months 6, 12 and up to Year 5</time_frame>
    <description>Change from baseline in the clinical severity of illness (CGI-Severity {CGI-S}).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions (Improvement)</measure>
    <time_frame>Months 6, 12 and up to Year 5</time_frame>
    <description>Clinical improvement from baseline (CGI-Improvement [CGI-I]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in adaptive behavior and functioning</measure>
    <time_frame>Months 6 and 12 and up to Year 3</time_frame>
    <description>Change from baseline in adaptive functioning using the Vineland Adaptive Behavior Scale (VABS-2) (2nd edition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in most troubling symptoms</measure>
    <time_frame>Months 6, 12 and up to Year 5</time_frame>
    <description>Change from baseline in the Visual Analog Scale for the Most Troubling Symptoms (VAS-MTS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in behavioral symptoms</measure>
    <time_frame>Months 6, 12 and up to Year 5</time_frame>
    <description>Change from baseline in the Child Behavior Checklist (CBCL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GCase (glucocerebrosidase) enzyme activity levels in blood</measure>
    <time_frame>Up to Year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GCase enzyme activity levels in CSF (cerebrospinal fluid)</measure>
    <time_frame>Up to Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycolipid levels in blood</measure>
    <time_frame>Up to Year 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glycolipid levels in CSF</measure>
    <time_frame>Up to Year 3</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Gaucher Disease, Type 2</condition>
  <arm_group>
    <arm_group_label>PR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PR001</intervention_name>
    <description>Participants will receive a single dose of PR001 administered intracisternally.</description>
    <arm_group_label>PR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Single IV pulse administered as concomitant medication.</description>
    <arm_group_label>PR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.</description>
    <arm_group_label>PR001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Administered orally as concomitant medication, followed by dose tapering.</description>
    <arm_group_label>PR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Bi-allelic GBA1 mutations consistent with a diagnosis of GD2 confirmed by the central&#xD;
             laboratory.&#xD;
&#xD;
          -  Neurological signs and/or symptoms consistent with diagnosis of GD2&#xD;
&#xD;
          -  Parent/legal guardian has the ability to understand the purpose and risks of the study&#xD;
             and provide written informed consent and authorization to use protected health&#xD;
             information in accordance with national and local privacy regulations.&#xD;
&#xD;
          -  Patient has a reliable informant (i.e., parent/legal guardian) willing and able to&#xD;
             participate in the study as a source of information on the patient's health status and&#xD;
             cognitive and functional abilities (including providing input into the rating scales).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of a significant CNS disease other than GD2 that may be a cause for the&#xD;
             patient's GD symptoms or may confound study objectives.&#xD;
&#xD;
          -  Achieved independent gait.&#xD;
&#xD;
          -  Severe peripheral symptoms of GD which, in the opinion of the Investigator, would pose&#xD;
             an unacceptable risk to the patient or interfere with the patient's ability to comply&#xD;
             with study procedures or interfere with the conduct of the study.&#xD;
&#xD;
          -  Concomitant disease, condition, or treatment which, in the opinion of the&#xD;
             Investigator, would pose an unacceptable risk to the patient or interfere with the&#xD;
             patient's ability to comply with study procedures or interfere with the conduct of the&#xD;
             study.&#xD;
&#xD;
          -  Use of any GD treatment-related substrate reduction therapy.&#xD;
&#xD;
          -  Use of strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) or P-glycoprotein&#xD;
             (P-gp) medications, herbals, or over-the-counter agents.&#xD;
&#xD;
          -  Any type of prior gene or cell therapy.&#xD;
&#xD;
          -  Immunizations (live vaccines) in the prior 4 weeks.&#xD;
&#xD;
          -  Use of blood thinners. Antiplatelet therapies are acceptable if the patient is&#xD;
             medically able to temporarily stop them from 7 days prior to dosing and through at&#xD;
             least 48 hours after the intracisternal injection and lumbar puncture.&#xD;
&#xD;
          -  Use of systemic immunosuppressant or corticosteroid therapy other than&#xD;
             protocol-specified (topical preparations for dermatological conditions are allowed).&#xD;
&#xD;
          -  Participation in another investigational drug or device study within the past 6&#xD;
             months.&#xD;
&#xD;
          -  Brain MRI (magnetic resonance imaging) and MRA (magnetic resonance angiography)&#xD;
             showing clinically significant abnormality considered to prevent intracisternal&#xD;
             injection.&#xD;
&#xD;
          -  Clinically significant laboratory test result abnormalities assessed at screening.&#xD;
&#xD;
          -  Contraindications or intolerance to radiographic visualization methods (e.g. MRI, MRA,&#xD;
             CT), and intolerance to contrast agents used for MRI or CT scans.&#xD;
&#xD;
          -  Contraindications to general anesthesia or sedation.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Travis Lewis, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Prevail Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prevail Therapeutics</last_name>
    <phone>(917) 336-9310</phone>
    <email>patients@prevailtherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital, 5700 Martin Luther King Jr Way</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Nicholas</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>5241</phone_ext>
      <email>jill.nicholas@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Children's Hospital, 2450 Riverside Avenue</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Gibson</last_name>
      <phone>612-672-7013</phone>
      <email>Cgibson1@fairview.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh, 4401 Penn Avenue</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Martin</last_name>
      <email>sausjl@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Klotz</last_name>
      <email>klotzse@upmc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Manchester Centre for Genomic Medicine, 6th Floor, St Mary's Hospital, Oxford Road</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Crowther</last_name>
      <phone>07815 987896</phone>
      <email>laura.crowther@mft.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gaucher Disease</keyword>
  <keyword>GD</keyword>
  <keyword>Gaucher</keyword>
  <keyword>Type 2 Gaucher</keyword>
  <keyword>Neuronopathic Gaucher</keyword>
  <keyword>nGD</keyword>
  <keyword>AAV9</keyword>
  <keyword>GBA</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>Glucocerebrosidase</keyword>
  <keyword>GBA1 mutation</keyword>
  <keyword>Infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

